ExoMatr™ — EV gels and creams for barrier-companion and recovery retail
ExoMatr™ is TONGNIAN's topical line: matrix-modified EV particles and hydrogels delivered as gels and creams for skin and mucosal barrier-companion programs. The matrix system modulates release and residence of the characterized EV payload; all formats run on the fully enclosed 0.5–5 L micro-batch platform, and every batch ships with a COA and characterization summary.
Who this line serves
- Compromised-barrier programs (18–25) — daily companion gels for skin that feels reactive and stressed.
- recovery-stage routines (35–55) — comfort gels within post-procedure and convalescent retail programs.
- Family-care shelves — gentle multi-purpose gels positioned beside diaper-care and sensitive-skin staples.
Line programs
| Program | Population | Dosage form | Status |
|---|---|---|---|
| Barrier-companion gel | Daily barrier care | Hydrogel, 30 g tube (sample) | Pilot-ready |
| Comfort repair cream | Recovery retail | Cream, 50 g jar (sample) | Pilot-ready |
| Mucosal-companion gel | Family-care programs | Multi-purpose gel (sample) | Format development |
What the matrix system changes
- Matrix-modulated release — the hydrogel matrix extends residence time of the EV payload at the application site.
- Gentle everyday formats — fragrance-minimal bases with preservative systems chosen for stressed skin.
- Line-extension friendly — one particle system, re-expressed across tube, jar, and sachet formats.
- Documented batches — batch COA with every shipment; payload and release consistency on retained samples.
Specs & characterization
| Item | Value |
|---|---|
| EV system | Matrix-modified EV particles in hydrogel carrier |
| Vesicle size (NTA) | 80–200 nm range by format (sample) |
| Formats | 30 g tube, 50 g jar, sachets (sample configurations) |
| QC panel | Payload & release consistency, NTA, TEM, endotoxin (LAL), microbial limits; batch COA |
| Storage | Cool, light-protected (sample); material line: −20 °C up to 60 days / −80 °C up to 360 days |
| Compliance status | EV material line: FDA DMF Type II 044197 · INCI 41316; finished good on the cosmetic track |
| Typical program | Pilot from 500 units · production from 2,000 units · standard lead 15 workdays |
Quality & compliance
- Cosmetic track — barrier-companion wording only; no wound-healing or therapeutic claims at retail.
- Material chain — DMF Type II 044197 and INCI 41316 on the EV material line; batch COAs with every shipment.
- Closed line — production on the fully enclosed 0.5–5 L micro-batch platform.
- Channel panels — extended test panels arranged per channel requirement.
Work with this line: start via Request a quote, or review the OBM program for family-care line builds.
Request a quote
Customize ExoMatr™ dosage forms and skin feel for your brand.
Share your brand stage and target category, and we’ll return sample specs, an MOQ framework, and characterization samples (typical: sample kits in 3–5 days); to review the full-line design first, head to Knowledge · Solutions.